Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 28 citing articles:

Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme
David J. Jackson, Girolamo Pelaia, Benjamin Emmanuel, et al.
European Respiratory Journal (2024) Vol. 64, Iss. 1, pp. 2301521-2301521
Open Access | Times Cited: 19
Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy
Hiroyuki Nagase, Maho Suzukawa, Keiji Oishi, et al.
Allergology International (2022) Vol. 72, Iss. 1, pp. 11-23
Open Access | Times Cited: 58
Pathobiology of Type 2 Inflammation in Asthma and Nasal Polyposis
Corrado Pelaia, Giulia Pelaia, Angelantonio Maglio, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 10, pp. 3371-3371
Open Access | Times Cited: 27
Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis
Corrado Pelaia, Claudia Crimi, Alida Benfante, et al.
Respirology (2024) Vol. 29, Iss. 10, pp. 869-879
Open Access | Times Cited: 13
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
Alessandra Vultaggio, Maria Aliani, Elena Altieri, et al.
Respiratory Research (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 20
Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study
Alicia Padilla, Isabel Carmona, Pilar Ausín, et al.
Respiratory Research (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 20
Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma
Alessandro Vatrella, Angelantonio Maglio, Corrado Pelaia, et al.
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2181-2181
Open Access | Times Cited: 25
The impact of blood eosinophil count and FeNO on benralizumab effectiveness in clinical practice: An ORBE II subanalysis
Ismael García‐Moguel, Álvaro Martínez-Mesa, Rubén Andújar Espinosa, et al.
Respiratory Medicine (2025), pp. 107940-107940
Closed Access
Real-world comparison of T2-biologics effectiveness in severe allergic asthma with nasal polyps
Angélica Tiotiu, Nicolas Migueres, Francisco Javier González‐Barcala, et al.
Respiratory Medicine (2025) Vol. 238, pp. 107979-107979
Closed Access
Benralizumab Outcomes in Patients with Severe Eosinophilic Asthma Treated in Real-Life Settings: Results of the BREEZE Study in 5 Countries From Central Eastern Europe and Baltics
Florin Mihălţan, Zsuzsanna Csoma, Norbert Pauk, et al.
Journal of Asthma and Allergy (2025) Vol. Volume 18, pp. 195-210
Open Access
Efficacy and safety of dupilumab as add-on therapy for patients with severe asthma: A real-world Dutch cohort study
John C. Thelen, Cathelijne M. van Zelst, Sigrid E. van Brummelen, et al.
Respiratory Medicine (2022) Vol. 206, pp. 107058-107058
Closed Access | Times Cited: 21
Benralizumab in severe eosinophilic asthma in real life: confirmed effectiveness and contrasted effect on sputum eosinophiliaversusexhaled nitric oxide fraction – PROMISE
Florence Schleich, Catherine Moermans, Laurence Seidel, et al.
ERJ Open Research (2023) Vol. 9, Iss. 6, pp. 00383-2023
Open Access | Times Cited: 11
Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a post hoc analysis from the ANANKE study
Luisa Brussino, Maria Aliani, Elena Altieri, et al.
Frontiers in Allergy (2025) Vol. 6
Open Access
Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
Maria D’Amato, Francesco Menzella, Elena Altieri, et al.
Frontiers in Allergy (2022) Vol. 3
Open Access | Times Cited: 17
Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting
Carolina Vitale, Angelantonio Maglio, Corrado Pelaia, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 3, pp. 985-985
Open Access | Times Cited: 9
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study
Paolo Cameli, Maria Aliani, Elena Altieri, et al.
Journal of Asthma and Allergy (2024) Vol. Volume 17, pp. 273-290
Open Access | Times Cited: 2
Early response to benralizumab in Canadian patients with severe eosinophilic asthma: Interim results from a prospective observational cohort
Stephen G. Noorduyn, Sheena Kayaniyil, Brett Lancaster, et al.
Canadian Journal of Respiratory Critical Care and Sleep Medicine (2024) Vol. 8, Iss. 3, pp. 99-107
Open Access | Times Cited: 2
Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis
Cristiano Caruso, Paolo Cameli, Elena Altieri, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 11
Comparison between clinical trials and real-world evidence studies on biologics for severe asthma
Francesco Menzella, Andrea Ballarin, Maria Cristina Sartor, et al.
Journal of International Medical Research (2022) Vol. 50, Iss. 11
Open Access | Times Cited: 9
Type 2 severe asthma: pathophysiology and treatment with biologics
Corrado Pelaia, J. Mark Melhorn, Timothy S.C. Hinks, et al.
Expert Review of Respiratory Medicine (2024) Vol. 18, Iss. 7, pp. 485-498
Closed Access | Times Cited: 1
Effectiveness of benralizumab in the Tokyo Asthma Study (TOAST): A real-world prospective interventional trial
Katsunori Masaki, Maho Suzukawa, Hitoshi Sasano, et al.
Allergology International (2024)
Open Access | Times Cited: 1
Criteria to evaluate efficacy of biologics in asthma: a Global Asthma Association survey
Angélica Tiotiu, András Bikov, Francisco Javier González‐Barcala, et al.
Expert Review of Respiratory Medicine (2023) Vol. 17, Iss. 6, pp. 507-516
Open Access | Times Cited: 2
Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study
Gianenrico Senna, Maria Aliani, Elena Altieri, et al.
Journal of Asthma and Allergy (2022) Vol. Volume 15, pp. 1593-1604
Open Access | Times Cited: 4
The effect of benralizumab on inflammation in severe asthma: a real-life analysis
Dina Visca, Francesco Ardesi, Martina Zappa, et al.
Therapeutic Advances in Respiratory Disease (2024) Vol. 18
Open Access
Pharmacologic Treatment of Type 2-High Severe Asthma
Annamaria Bosi, Maria Serena Simeone, Federica Ghinassi, et al.
Medical Research Archives (2024) Vol. 12, Iss. 4
Open Access
Page 1 - Next Page

Scroll to top